Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 11/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MYC | P01106 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6279450 | 0.88 | MEN1 (0.65) | MEN1KMT2AMAPTKDM4EPOLB | |
| SCHEMBL6282767 | 0.83 | MAPT (0.59) | MEN1KMT2AMAPTKDM4EPOLB | |
| SCHEMBL1905909 | 0.82 | MEN1 (0.65) | MEN1KMT2AMAPTKDM4EPOLB | |
| SCHEMBL1903643 | 0.82 | MEN1 (1.00) | MEN1KMT2AMAPTKDM4EPOLB | |
| SCHEMBL1900966 | 0.81 | MEN1 (0.71) | MEN1KMT2AMAPTKDM4EPOLB | |
| SCHEMBL1903075 | 0.81 | MEN1 (0.79) | MEN1KMT2AMAPTKDM4EPOLB | |
| SCHEMBL5134545 | 0.81 | MEN1 (0.61) | MEN1KMT2AMAPTKDM4EPOLB | |
| SCHEMBL3253053 | 0.79 | MEN1 (0.61) | MEN1KMT2AMAPTKDM4EPOLB | |
| SCHEMBL1901745 | 0.79 | MEN1 (0.76) | MEN1KMT2AMAPTKDM4EPOLB | |
| SCHEMBL1905681 | 0.78 | MEN1 (0.60) | MEN1KMT2AMAPTKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | MEN1 2361/4885KMT2A 629/4885MAPT 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.